Genitourinary Cancer

SS 41 - GU 5 - Discoveries for High Risk and Recurrent Prostate Cancer

297 - Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed Stereotactic Body Radiation Therapy

Wednesday, October 24
1:30 PM - 1:40 PM
Location: Room 214 A/B

Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed Stereotactic Body Radiation Therapy
J. D. Evans1, L. K. Morris1, H. Dong2,3, S. Cao2, X. Liu2, K. Mara4, B. J. Stish1, B. J. Davis1, K. Olivier1, A. S. Mansfield5, R. S. Dronca5, M. J. Iott1, E. D. Kwon3, R. L. Foote1, and S. S. Park1; 1Department of Radiation Oncology, Mayo Clinic, Rochester, MN, 2Department of Immunology, Mayo Clinic, Rochester, MN, 3Department of Urology, Mayo Clinic, Rochester, MN, 4Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, 5Division of Medical Oncology, Mayo Clinic, Rochester, MN

Purpose/Objective(s): To prospectively observe CD8+ T-cell immunophenotypic changes in prostate cancer (PCa) patients treated with metastasis-directed stereotactic body radiation therapy (mdSBRT) and correlate these phenotypic changes with clinical outcomes.

Materials/Methods: We prospectively analyzed peripheral blood mononuclear cells (PBMCs) that were isolated – before and at multiple time points after mdSBRT – from 37 patients enrolled between January 2013 and October 2014 with recurrent oligometastatic PCa (≤3 extracranial sites). Immunophenotyping was performed on isolated PBMCs using flow cytometry to identify subpopulations of circulating CD8+ T-cells including Tumor-Reactive (TTR; PD-1+CD11ahigh), Effector Memory (TEM; CCR7-CD45RA-), Central Memory (TCM; CCR7+CD45RA-), Effector (TEF; CCR7-CD45RA+), and Naïve (TN; CCR7+CD45RA+) T-cells. Univariate Cox proportional hazards regression was used to assess whether changes in these T-cell subpopulations were potential risk factors for death and progression. Kaplan-Meier method was used for survival. Cumulative incidence for progression and new distant metastasis (NDM) was estimated considering death as a competing risk.

Results: Median follow-up was 39 months (IQR 34-43). Overall survival at 3 years was 78.2%. Cumulative incidence for local progression at 3 years was 16.5% and for NDM at 3 years was 67.6%. Androgen deprivation therapy (ADT) was given concurrently with mdSBRT vs. delayed until additional progression for 19 (51%) and 18 (49%) patients, respectively. Concurrent ADT was protective against the risk of NDM (HR 0.44; 95% CI 0.20-0.96; p=0.039). Median time to NDM was 28 (IQR 5-41) vs. 8 (IQR 4-12) months for concurrent vs. delayed ADT, respectively. Seven out of 7 (100%) patients that continue to remain progression-free received concurrent ADT with mdSBRT. An increase in the TCM cell subpopulation between baseline and day 14 after mdSBRT was associated with the risk of death (HR 1.22; 95% CI 1.02-1.47; p=0.033). An increase in the TTR cell subpopulation between baseline and day 14 was protective against the risk of local progression (HR 0.80; 95% CI 0.65-0.98; p=0.032). Relative increases ≥1% in the TTR cell subpopulation between baseline and day 14 were associated with a non-significant protective effect against the risk of any progression, distant or local (HR 0.42; 0.17-1.01; p=0.052).

Conclusion: Prospective CD8+ T-cell immunophenotyping before and after mdSBRT in patients with oligometastatic PCa provided insight into clinical outcomes. An increase in the TCM cell subpopulation was associated with the risk of death. An increase in the TTR cell subpopulation was protective against the risk of local progression. Concurrent ADT with mdSBRT was protective against the risk of NDM. This is the first report to show that an increase in the TTR cell subpopulation after mdSBRT is associated with PCa disease control, and has implications for combining mdSBRT and adoptive cell transfer therapies. Supported by NCI R01 CA200551.

Author Disclosure: J.D. Evans: None. L.K. Morris: None. H. Dong: None. S. Cao: None. B.J. Davis: Consultant; Prospect Medical Inc, UpToDate Inc. Advisory Board; Prospect Medical Inc. Stock; Pfizer. Chair, Written Boards in GU Radiation Oncology; American Board of Radiology. Chair, Appropriateness Committee on Prostate Cance; American College of Radiology. K. Olivier: Stock; ViewRay Incorporated. A.S. Mansfield: Honoraria; BMS, Genentech, In. Lung Cancer Education Committee; ASCO. M.J. Iott: None. R.L. Foote: Employee; Mayo Clinic. Consultant; Up to Date. Royalty; Elsevier. Co-chair; ABR. Chair, Department of Radiation Oncology; Mayo Clinic.

Send Email for Jaden Evans


Assets

297 - Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed Stereotactic Body Radiation Therapy



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Prospective Immunophenotyping of CD8+ T-cells and Associated Clinical Outcomes of Patients With Oligometastatic Prostate Cancer Treated With Metastasis-Directed Stereotactic Body Radiation Therapy